SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November
26, 2021
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
000-19125
|
|
33-0336973
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
2855 Gazelle Court
Carlsbad, CA
92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code:
(760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
|
Common Stock, $.001 Par Value |
|
“IONS”
|
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(Section 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (Section 240.12b-2 of this chapter).
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
|
On November 19, 2021, Peter N. Reikes, a member of the Board of
Directors (“Board”) and Finance Committee of the Board of Ionis
Pharmaceuticals, Inc. (the “Company”), notified the Company that he
is resigning from the Company’s Board effective November 21, 2021.
Mr. Reikes has accepted a position with the U.S. Food and Drug
Administration that requires him to step off the Company’s Board to
avoid a perception of a conflict of interest. The Company thanks
Mr. Reikes for his advice and leadership as a member of the
Company’s Board. The Company wishes Mr. Reikes success in his new
endeavor.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
Ionis Pharmaceuticals, Inc.
|
| |
|
|
Dated: November 26, 2021
|
By:
|
/s/ Patrick R. O’Neil
|
|
|
|
Patrick R. O’Neil
|
|
|
|
Executive Vice President, Chief Legal Officer and General
Counsel
|
